Sustained peptide-release formulation
US7309689B2 · kind B2 · utility
4Cited by
7References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2004 |
| Grant date | Dec 18, 2007 |
| Priority date | — |
| Expiry date | Dec 18, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.